Objective:

To correct inaccuracies in the previously published table of FDA-approved immune checkpoint inhibitor combination therapies.

Approach:

Key Findings:

• Certain FDA-approved ICI combination therapies were omitted in the original publication.
• The corrected table now accurately reflects the FDA approvals as of July 2024.
• Clarifications were made to ensure consistency in the text regarding pembrolizumab's approval.

Interpretation:

The corrections enhance the accuracy and reliability of the information regarding combination therapies for immune checkpoint inhibitors.

Limitations:

• The article only addresses corrections and does not present new research findings.
• Focus is limited to FDA-approved therapies, excluding other potential combinations.

Conclusion:

The corrections provide a comprehensive and accurate overview of FDA-approved combination immunotherapies involving ICIs.

Sources:

• Frontiers in Immunology
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.